Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jul 1;98(1):30–35. doi: 10.1172/JCI118773

Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome.

T Yamamoto 1, K Ozono 1, S Kasayama 1, K Yoh 1, K Hiroshima 1, M Takagi 1, S Matsumoto 1, T Michigami 1, K Yamaoka 1, T Kishimoto 1, S Okada 1
PMCID: PMC507397  PMID: 8690800

Abstract

McCune-Albright syndrome (MAS) is characterized by café-au-lait spot, multiple endocrine hyperfunction, and polyostotic fibrous dysplasia. A somatic point mutation of Gsalpha protein was reported to decrease GTPase activity, leading to increase in the GSalpha-associated hormone actions via cAMP. IL-6 is known to stimulate osteoclast formation and in the IL-6 promoter, a cAMP responsive element has been identified. In this paper, we investigated the role of IL-6 in the bone lesions of MAS, using the isolated fibrous cells from the polyostotic fibrous dysplasia tissues in bones of the two patients with MAS. Bone biopsy specimen revealed the increased osteoclast in number. In both patients, a GSalpha mutation (Arg201 -> His) was identified in the cultured fibrous cells. Intracellular cAMP content and IL-6 secretion by the patient cells were increased. Rp-8Br-cAMP significantly inhibited IL-6 production in the patient cells, while it had no effect on normal control. The addition of dibutyryl cAMP significantly increased the synthesis of IL-6 in normal control cells. In contrast, no effect of dibutyryl cAMP on IL-6 synthesis was observed in the cells from one of the MAS patients. These data suggest that IL-6 is, at least, one of the downstream effectors of cAMP and that the increased IL-6 synthesis has a pathogenic role in the bone lesions of MAS patients via increasing the number of osteoclasts. These results may provide a new strategy for the therapy of MAS patients.

Full Text

The Full Text of this article is available as a PDF (372.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abate C., Curran T. Encounters with Fos and Jun on the road to AP-1. Semin Cancer Biol. 1990 Feb;1(1):19–26. [PubMed] [Google Scholar]
  2. Candeliere G. A., Glorieux F. H., Prud'homme J., St-Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med. 1995 Jun 8;332(23):1546–1551. doi: 10.1056/NEJM199506083322304. [DOI] [PubMed] [Google Scholar]
  3. Chao A. C., de Sauvage F. J., Dong Y. J., Wagner J. A., Goeddel D. V., Gardner P. Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J. 1994 Mar 1;13(5):1065–1072. doi: 10.1002/j.1460-2075.1994.tb06355.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dendorfer U., Oettgen P., Libermann T. A. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol. 1994 Jul;14(7):4443–4454. doi: 10.1128/mcb.14.7.4443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elias J. A., Tang W., Horowitz M. C. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology. 1995 Feb;136(2):489–498. doi: 10.1210/endo.136.2.7835281. [DOI] [PubMed] [Google Scholar]
  6. FROST H. M. Preparation of thin undecalcified bone sections by rapid manual method. Stain Technol. 1958 Nov;33(6):273–277. doi: 10.3109/10520295809111862. [DOI] [PubMed] [Google Scholar]
  7. Gaiddon C., Boutillier A. L., Monnier D., Mercken L., Loeffler J. P. Genomic effects of the putative oncogene G alpha s. Chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells. J Biol Chem. 1994 Sep 9;269(36):22663–22671. [PubMed] [Google Scholar]
  8. Girasole G., Passeri G., Jilka R. L., Manolagas S. C. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994 Apr;93(4):1516–1524. doi: 10.1172/JCI117130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jilka R. L., Hangoc G., Girasole G., Passeri G., Williams D. C., Abrams J. S., Boyce B., Broxmeyer H., Manolagas S. C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992 Jul 3;257(5066):88–91. doi: 10.1126/science.1621100. [DOI] [PubMed] [Google Scholar]
  10. Landis C. A., Masters S. B., Spada A., Pace A. M., Bourne H. R., Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989 Aug 31;340(6236):692–696. doi: 10.1038/340692a0. [DOI] [PubMed] [Google Scholar]
  11. Lee P. A., Van Dop C., Migeon C. J. McCune-Albright syndrome. Long-term follow-up. JAMA. 1986 Dec 5;256(21):2980–2984. [PubMed] [Google Scholar]
  12. Liens D., Delmas P. D., Meunier P. J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994 Apr 16;343(8903):953–954. doi: 10.1016/s0140-6736(94)90069-8. [DOI] [PubMed] [Google Scholar]
  13. McKinley D., Wu Q., Yang-Feng T., Yang Y. C. Genomic sequence and chromosomal location of human interleukin-11 gene (IL11). Genomics. 1992 Jul;13(3):814–819. doi: 10.1016/0888-7543(92)90158-o. [DOI] [PubMed] [Google Scholar]
  14. O'Doherty D. P., Bickerstaff D. R., McCloskey E. V., Hamdy N. A., Beneton M. N., Harris S., Mian M., Kanis J. A. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res. 1990 May;5(5):483–491. doi: 10.1002/jbmr.5650050510. [DOI] [PubMed] [Google Scholar]
  15. Roodman G. D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., Smith J. F., Singer F. R. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992 Jan;89(1):46–52. doi: 10.1172/JCI115584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schwindinger W. F., Francomano C. A., Levine M. A. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5152–5156. doi: 10.1073/pnas.89.11.5152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shenker A., Chanson P., Weinstein L. S., Chi P., Spiegel A. M., Lomri A., Marie P. J. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet. 1995 Sep;4(9):1675–1676. doi: 10.1093/hmg/4.9.1675. [DOI] [PubMed] [Google Scholar]
  18. Shenker A., Weinstein L. S., Moran A., Pescovitz O. H., Charest N. J., Boney C. M., Van Wyk J. J., Merino M. J., Feuillan P. P., Spiegel A. M. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993 Oct;123(4):509–518. doi: 10.1016/s0022-3476(05)80943-6. [DOI] [PubMed] [Google Scholar]
  19. Shenker A., Weinstein L. S., Sweet D. E., Spiegel A. M. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab. 1994 Sep;79(3):750–755. doi: 10.1210/jcem.79.3.8077356. [DOI] [PubMed] [Google Scholar]
  20. Spiegel A. M., Shenker A., Weinstein L. S. Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction. Endocr Rev. 1992 Aug;13(3):536–565. doi: 10.1210/edrv-13-3-536. [DOI] [PubMed] [Google Scholar]
  21. Utiger R. D. Subclinical hyperthyroidism--just a low serum thyrotropin concentration, or something more? N Engl J Med. 1994 Nov 10;331(19):1302–1303. doi: 10.1056/NEJM199411103311909. [DOI] [PubMed] [Google Scholar]
  22. Weinstein L. S., Shenker A., Gejman P. V., Merino M. J., Friedman E., Spiegel A. M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991 Dec 12;325(24):1688–1695. doi: 10.1056/NEJM199112123252403. [DOI] [PubMed] [Google Scholar]
  23. Yamamoto T., Ecarot B., Glorieux F. H. In vivo osteogenic activity of isolated human bone cells. J Bone Miner Res. 1991 Jan;6(1):45–51. doi: 10.1002/jbmr.5650060109. [DOI] [PubMed] [Google Scholar]
  24. Yamamoto T., Kurihara N., Yamaoka K., Ozono K., Okada M., Yamamoto K., Matsumoto S., Michigami T., Ono J., Okada S. Bone marrow-derived osteoclast-like cells from a patient with craniometaphyseal dysplasia lack expression of osteoclast-reactive vacuolar proton pump. J Clin Invest. 1993 Jan;91(1):362–367. doi: 10.1172/JCI116194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yamaoka K., Tanaka H., Kurose H., Shima M., Ozono K., Nakajima S., Seino Y. Effect of single oral phosphate loading on vitamin D metabolites in normal subjects and in X-linked hypophosphatemic rickets. Bone Miner. 1989 Sep;7(2):159–169. doi: 10.1016/0169-6009(89)90073-1. [DOI] [PubMed] [Google Scholar]
  26. Yoneda T., Nakai M., Moriyama K., Scott L., Ida N., Kunitomo T., Mundy G. R. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res. 1993 Feb 15;53(4):737–740. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES